# Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients

> **NCT02242279** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 37 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** BEA 2180 BR
- **DRUG:** Tiotropium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02242279
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2004-12
- **Final completion:** —
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2014-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02242279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02242279, "Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02242279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*